Silverback Therapeutics gets $78M boost to 'reconceptualize' antibody-drug conjugates
The resurgence of antibody-drug conjugates (ADCs), in which a cancer-killing toxin is attached to a specific antibody using a biodegradable linker, has offered the thriving field of oncology another potent weapon in the fight against cancer. But what if this trojan horse technology could be tweaked to link immune-stimulatory agents — as opposed to cytotoxic payloads — to monoclonal antibodies?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.